BIA-ALCL and Breast Implant Safety in Decatur, Alabama

What is BIA-ALCL?

The full name is breast implant-associated anaplastic large cell lymphoma. A capsule is the scar tissue the body forms around an implant. In many cases, the lymphoma is found in that capsule or the fluid beside it. It can also spread beyond this area, making timely diagnosis and treatment important. ^[10]

BIA-ALCL has occurred after cosmetic breast augmentation and after implant-based breast reconstruction. Both saline-filled and silicone-filled implants have been involved. A history of breast cancer is not required for this diagnosis. ^[2]

A breast change cannot be classified from an online description alone. The consultation should consider your symptoms, previous operations, implant records, examination, and any necessary tests.

Symptoms and when to seek care

The American Society of Plastic Surgeons lists breast enlargement or new asymmetry, a fluid collection, a breast or underarm lump, pain, hardening, and sometimes a skin rash. Symptoms often appear years after implantation, commonly around eight to ten years, but that timing is not a rule for deciding whether to seek care. ^[2]

Tell the clinician when the change began, whether one or both sides are affected, and whether swelling is increasing or keeps returning. Mention previous implants and temporary tissue expanders, even if your current implants are different.

Similar symptoms can have other explanations, including implant leakage or an injury. A new fluid collection should be evaluated rather than assumed to be harmless. Ask who will arrange the assessment and how soon you should be seen. ^[5]

If you have already had fluid drained or testing elsewhere, bring the reports and ask whether the specimen was evaluated specifically for implant-associated lymphoma. Tell the clinician if the swelling has returned.

Textured, smooth, saline, and silicone implants

Texture describes the implant’s outer surface; saline and silicone describe the filling. The FDA says implant fill does not appear to be a BIA-ALCL risk factor based on available evidence, although the data have limitations. Having a saline implant therefore does not remove the need to consider its surface and history. ^[1]

Avoid interpreting “smooth” as a guarantee of zero risk. In its table through June 30, 2024, the FDA lists reports involving smooth implants, including one with no known textured implant history, and notes that prior-device information is often incomplete. The established concern remains greatest with textured exposure. ^[3]

Find your implant card and operation records. If you have neither, ask the original surgeon or surgical facility; an implant manufacturer’s device-tracking records may also help. Record the manufacturer, model, placement dates, and every previous implant or expander. ^[5]

If you are considering a first operation, our breast augmentation guide covers broader planning questions. Ask the surgeon to explain the proposed implant’s surface as well as its size and filling.

Understanding BIA-ALCL risk estimates

There is no single lifetime-risk figure that applies equally to every textured implant. Manufacturer, surface, patient group, and duration of follow-up affect estimates. The ASPS patient advisory summarizes published estimates ranging from about 1 in 355 to 1 in 30,000 among women with textured implants. This is a range across studies, not a personalized prediction. ^[10]

Ask which evidence applies to your exact device and how long the patients in that study were followed. Avoid treating a population average as a precise answer for your situation, or comparing numbers drawn from different implant types as if they measure the same exposure.

The FDA’s published reporting table reviewed for this guide covers data through June 30, 2024 and lists 1,380 reported BIA-ALCL cases in the United States and elsewhere. Cases affecting both breasts count twice. These are dated surveillance data, not a count through September 2026. ^[3]

Reports cannot establish the frequency of disease by themselves. Missing histories, underreporting, possible duplicates, and uncertainty about how many people used a device limit what can be calculated from the FDA database. Do not divide a reported case total by an unrelated implant-sales number to estimate personal risk. ^[3]

What the Allergan BIOCELL recall means

On July 24, 2019, the FDA requested a recall of certain Allergan BIOCELL textured implants and tissue expanders, and Allergan announced a worldwide recall. The action included specific saline and silicone products and removed unused affected devices from the market. It did not mean that every person with an implanted device needed an operation. ^[4]

Check the model rather than relying on the manufacturer’s name alone. The recall concerned specified BIOCELL products, not every breast implant. Ask your clinician to match your records to the recalled models and explain what follow-up is appropriate. ^[4]

Keep copies of the information you obtain. If the original practice has closed, ask the hospital or surgery center where your operation took place how to request your operative record.

How BIA-ALCL is diagnosed

Evaluation commonly starts with an examination and ultrasound to look for fluid, a mass, or abnormal lymph nodes. MRI may be used when ultrasound does not resolve the concern. A clinician may arrange image-guided fluid sampling or a biopsy, depending on the findings. ^[6]

The fluid needs appropriate laboratory examination, including assessment of the cells and testing for CD30 and other markers. BIA-ALCL characteristically has CD30-positive, ALK-negative tumor cells. CD30 staining alone is not the whole diagnosis; the pathologist interprets it with cell appearance and other findings. ^[6]

Draining fluid can provide a diagnostic specimen, but drainage alone does not treat lymphoma. Repeat drainage may also make diagnosis harder by reducing the available tumor cells. Ask the team to coordinate specimen handling with a laboratory experienced in this condition. ^[6]

If a sample is inadequate or symptoms continue despite an initial reassuring result, ask what further review is needed. Bring the pathology report to the next appointment so the team can see exactly what was tested.

There is no established screening test for BIA-ALCL in people without symptoms. A routine blood test or a normal screening mammogram should not be used as an answer to a new implant-related change. ^[5]

What if you have textured implants but no symptoms?

The FDA does not recommend routine removal of breast implants solely because of BIA-ALCL concern in people without symptoms. Continue routine care and discuss your device history, concerns, and follow-up with your clinician. ^[1]

Recommendations about elective removal have been debated. A 2024 American Association of Plastic Surgeons consensus statement considered preventive removal of certain textured implants reasonable in selected circumstances. In its response, ASPS said the evidence cited did not demonstrate a reduction in BIA-ALCL risk and continued to support FDA guidance. ^[7]

ASPS also supports patient choice and shared decision-making. You can discuss removal even if you do not have symptoms. Ask about your particular implant, operative risks, other reasons for revision, and how uncertainty about preventive benefit affects the decision. ^[7]

A useful appointment should leave you with a plan you understand: the next routine visit, the changes that should trigger an earlier call, and the options if you later decide you want removal.

Implant exchange, capsulectomy, and “en bloc” removal

A capsulectomy removes scar tissue surrounding an implant. Partial removal leaves some capsule behind; total removal takes out the entire capsule. “Total intact” describes removal in one piece. An en bloc operation also removes a margin of surrounding uninvolved tissue for suspected or established implant-associated cancer after an appropriate workup. ^[8]

These terms should not be used interchangeably. The Breast Surgery Collaborative Community reserves en bloc capsulectomy for that cancer-related indication. It is not a standard requirement for every elective implant removal, and a more extensive procedure can carry additional risks. ^[8]

The same consensus says it remains unknown whether removing implants, with or without a capsulectomy, prevents a future implant-associated cancer. Changing to smooth implants or removing the capsule should not be described as a guarantee that risk has been eliminated. ^[8]

Ask the surgeon to name the proposed operation, explain why that amount of capsule removal is appropriate, and discuss the likely effect on breast shape or reconstruction. If cancer is suspected, diagnostic evaluation should inform the surgical plan.

Treatment after a confirmed BIA-ALCL diagnosis

A confirmed diagnosis calls for a team experienced in this lymphoma, including surgical and oncology specialists. Staging, often with PET/CT, helps establish whether disease is confined around the implant or has spread. The findings guide treatment rather than a single operation being appropriate for everyone. ^[2]

For disease confined around the implant, complete surgical removal of the implant, involved capsule, and any associated mass is central to treatment. An 87-patient study found better outcomes with complete excision than with incomplete approaches. Its findings support careful surgical planning; they do not guarantee an individual outcome. ^[9]

Many patients with early disease can be treated successfully with surgery. Disease that cannot be fully removed, involves lymph nodes, or has spread may require cancer medicines and sometimes radiation. Your oncology team should explain the stage, the treatment goal, and the follow-up plan. ^[10]

Ask whether the opposite breast requires evaluation or treatment, who will review the pathology, and how the team will coordinate reconstruction decisions. Keep copies of the final diagnosis, staging scans, operation report, and follow-up schedule.

Ask the treating physician about reporting the case to the PROFILE registry. The Plastic Surgery Foundation accepts clinician reports to improve information about implant-associated cancers; patients are directed to ask their physician to submit their case. ^[17]

Follow-up and other breast implant concerns

BIA-ALCL is also distinct from breast implant illness (BII), a term used for reported systemic symptoms such as fatigue, brain fog, and joint or muscle problems. The FDA says BII does not currently have a formal diagnostic definition or a specific test. Those symptoms deserve clinical evaluation rather than being assumed to establish lymphoma. ^[13]

The FDA has separately reported squamous cell carcinoma and other lymphomas in the implant capsule. These conditions are not BIA-ALCL. Their rarity does not make a new breast change suitable for self-diagnosis; the clinician and laboratory must determine the cause. ^[12]

Implants also have noncancerous complications, including rupture and capsular contracture. They are not lifetime devices, and additional surgery may be needed over time. Continue the monitoring plan recommended for your implant type and medical history. ^[11]

Costs, insurance, and practical planning

Separate the cost discussion into evaluation of a new symptom, treatment of a confirmed diagnosis, and elective removal or exchange. Ask the practice and insurer about consultation, imaging, pathology, surgeon and facility fees, anesthesia, and follow-up. Get the required referrals and authorization details in writing.

Do not assume that a recall automatically pays for surgery, or that every implant-related procedure is excluded. The FDA cautions that removal or replacement may not be covered even when complications occur. Coverage depends on the proposed care and your policy; a manufacturer’s warranty is a separate arrangement. ^[14]

If a lymphoma is diagnosed, ask for help from the cancer team’s financial counselor with authorizations and treatment planning. For elective surgery, request a written estimate and clarification of what happens if the plan changes after testing.

Finding appropriate care near Decatur

For a new breast change, contact your implant surgeon, primary care clinician, or breast specialist and explain the symptom and implant history. Ask whether the practice can arrange the necessary imaging and pathology and refer you to a team experienced in BIA-ALCL when needed. If your original surgeon is unavailable, seek another clinician rather than delaying assessment.

When comparing clinicians in Decatur, Huntsville, or Athens, check the physician’s license and public actions through the Alabama Board of Medical Examiners. Specialty credentials need separate verification. ^[15]

You can check a plastic surgeon’s certification through the American Board of Plastic Surgery. Also ask about experience evaluating implant-associated swelling and access to an appropriate pathology and oncology team. ^[16]

Common questions

Does a new symptom mean I have cancer?

No. The reason for testing is to determine the cause. Tell the clinician what has changed and ask for a clear plan to investigate it rather than relying on an online risk estimate.

Should a recalled implant be removed immediately?

A recall alone does not establish that you need surgery. Arrange a discussion about your device and circumstances; if you have symptoms, explain them when you call. See the sections on the recall and care without symptoms above.

Can I just exchange textured implants for smooth ones?

Exchange is one option to discuss, but it is an operation with its own risks. First clarify whether you need diagnostic evaluation and what the proposed procedure can and cannot accomplish. The capsule-removal section explains why no option should be presented as a guarantee of preventing cancer.

Will I need chemotherapy if BIA-ALCL is confirmed?

Not everyone does. Treatment depends on stage and whether the disease can be completely removed. Ask the cancer team why it recommends surgery alone or additional therapy in your case. ^[9]

Sources and further reading

Resources checked September 22, 2026. Reporting totals and individual publications have their own dates, identified above where relevant. This guide updates the supplied historical article; it does not reproduce the former surgeon’s personal clinical experience or offer services on that practice’s behalf. This page has not been reviewed by a clinician on behalf of this website.

1. U.S. Food and Drug Administration. Questions and answers about BIA-ALCL.
2. American Society of Plastic Surgeons. BIA-ALCL disease summary.
3. U.S. Food and Drug Administration. Medical device reports of BIA-ALCL; data through June 30, 2024.
4. U.S. Food and Drug Administration. Allergan BIOCELL recall announcement, July 24, 2019.
5. American Society of Plastic Surgeons. BIA-ALCL frequently asked questions.
6. Jaffe ES et al. Journal of Clinical Oncology, 2020. Best Practices Guideline for the Pathologic Diagnosis of Breast Implant–Associated Anaplastic Large-Cell Lymphoma.
7. American Society of Plastic Surgeons. Response to AAPS recommendation regarding textured implant removal, 2024.
8. Breast Surgery Collaborative Community / American Society of Plastic Surgeons. Consensus statement on breast implant capsulectomy definitions and management, June 12, 2024.
9. Clemens MW et al. Journal of Clinical Oncology, 2016. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
10. American Society of Plastic Surgeons. BIA-ALCL patient advisory; includes study-dependent risk estimates.
11. U.S. Food and Drug Administration. Risks and complications of breast implants.
12. U.S. Food and Drug Administration. Reports of squamous cell carcinoma in the capsule around breast implants; safety communication, March 8, 2023.
13. U.S. Food and Drug Administration. Medical device reports for systemic symptoms in women with breast implants.
14. U.S. Food and Drug Administration. Things to consider before getting breast implants.
15. Alabama Board of Medical Examiners and Medical Licensure Commission. Licensee search.
16. American Board of Plastic Surgery. Verify certification.
17. The Plastic Surgery Foundation. PROFILE registry.